Peptide dosing charts

Synthetic pentadecapeptide

Animal studies frequently use ~10 mcg/kg. Research-community protocols commonly reference 200–500 mcg per day, often split. Human clinical dosing is not established.

Synthetic actin-binding peptide fragment

Research-community references commonly cite ~2–2.5 mg once or twice weekly during an initial period, tapering thereafter. Not established in humans.

Copper-binding tripeptide (Gly-His-Lys)

Topical cosmetic formulations commonly use 0.05–2%. Reconstituted research protocols commonly reference 1–2 mg per subcutaneous injection, daily or every other day in 4–8 week cycles (the solution appears faintly blue-green). Copper load is a research consideration, and human injectable dosing is not formally established.

Growth-hormone-releasing hormone (GHRH) analog

Research references commonly cite ~100 mcg per dose for the no-DAC form, frequently paired with a ghrelin-receptor agonist; DAC references ~1–2 mg weekly. Not established in humans.

Ghrelin-receptor agonist (GH secretagogue)

Research references commonly cite ~100–300 mcg per dose, one to three times daily, frequently paired with a GHRH analog. Not established in humans.

Growth-hormone-releasing hormone (GHRH) analog

Research references commonly cite ~100–300 mcg, often pre-sleep to align with natural GH pulses. Historical clinical use was as a diagnostic agent.

Stabilized GHRH analog

Its approved clinical regimen is ~2 mg subcutaneously once daily. This is a labeled human indication, distinct from most entries here.

Growth-hormone-releasing peptide (ghrelin-receptor agonist)

Research references commonly cite ~100–300 mcg per dose, often paired with a GHRH analog. Not established for general human use.

Growth-hormone-releasing peptide (ghrelin-receptor agonist)

Research references commonly cite ~100–300 mcg per dose. Marked hunger is a commonly noted research effect. Not established for general human use.

Growth-hormone-releasing peptide (ghrelin-receptor agonist)

Research references commonly cite ~100 mcg per dose; desensitization with sustained frequent use is a noted research consideration. Not established for human use.

Recombinant IGF-1 analog

As a research reagent, references vary widely (commonly ~20–50 mcg ranges in animal work). Not established or appropriate as a human therapeutic.

GLP-1 receptor agonist

Approved clinical regimens titrate slowly — e.g., 0.25 mg weekly up to 2.4 mg weekly for weight management — to manage gastrointestinal tolerability. Titration is central to its clinical use.

Dual GIP / GLP-1 receptor agonist

Approved regimens titrate from 2.5 mg weekly up to 15 mg weekly over months. Slow titration is central to tolerability.

Triple GIP / GLP-1 / glucagon receptor agonist

Clinical trials studied slow titration up to ~12 mg weekly. It remains investigational and is not approved for human use.

Mitochondrial-derived peptide

Preclinical and research-community references vary widely (commonly cited in ~5–10 mg weekly ranges, split). Not established in humans.

Cellular coenzyme (not a peptide; included as a research cofactor)

Research references span a wide range (e.g., ~100–500 mg subcutaneous references, plus IV protocols). Oral precursors are studied separately. Not an established therapeutic here.

Synthetic tetrapeptide

Research-community references commonly cite ~5–10 mg per day across short cycles (e.g., 10–20 days). Human clinical evidence is limited.

Melanocortin receptor agonist

Its approved regimen is 1.75 mg subcutaneously as needed before anticipated activity, with a per-day and per-month cap. Nausea is a common labeled effect.

Melanocortin receptor agonist

Research-community references cite small amounts (~0.25–1 mg) during an initial period. It is unapproved; moles/pigmentation changes and nausea are noted research safety considerations.

Synthetic heptapeptide (tuftsin analog)

Research references commonly cite ~250–500 mcg intranasally. Most human data comes from Russian clinical research; it is not FDA-approved.

Synthetic ACTH(4-10) fragment analog

Research references commonly cite ~200–600 mcg intranasally. Most human evidence is from Russian clinical research; it is not FDA-approved.

Modified growth-hormone fragment

Research references commonly cite ~300 mcg per day. Clinical obesity trials did not achieve approval for that indication.

Long-acting amylin analog

Investigational. Obesity trials escalated once-weekly subcutaneous doses up to roughly 2.4 mg; in the CagriSema combination it is paired 1:1 with semaglutide (2.4 mg + 2.4 mg). Not approved as a standalone product.

GLP-1 / glucagon dual receptor agonist

Investigational. Phase 2 obesity trials escalated once-weekly subcutaneous doses up to roughly 4.8 mg, and it has also been studied in MASH. Not approved.

GLP-1 / glucagon dual receptor agonist (oxyntomodulin analog)

Approved in China (2025) for chronic weight management; investigational elsewhere. Phase 3 programs studied once-weekly subcutaneous doses in roughly the 4-6 mg range.

Small-molecule NNMT inhibitor (not a peptide)

No established human clinical dosing; effects on fat metabolism are from cell and animal studies. Research-community sources reference oral doses in the tens-of-milligrams range, without clinical validation.

Mitochondria-targeting tetrapeptide

Investigational (as elamipretide). Clinical trials in mitochondrial disease and related conditions used roughly 40 mg/day subcutaneously. Not approved.

Mitochondrial-derived peptide

No established human dosing; research is preclinical, largely using potent analogs such as HNG.

Immunomodulatory 28-amino-acid peptide

Approved in a number of countries (as Zadaxin) — commonly 1.6 mg subcutaneously, often twice weekly, for hepatitis and as an immune adjuvant. Not FDA-approved in the United States.

Cathelicidin-derived antimicrobial peptide

No established human dosing; work is largely preclinical, spanning antimicrobial, wound-healing, and immunomodulatory models.

Alpha-MSH-derived tripeptide

No established human dosing; anti-inflammatory effects are reported mainly in cell and rodent gut-inflammation models. Research-community sources reference oral and subcutaneous use.

Synthetic octapeptide (tight-junction regulator)

Investigational (as larazotide acetate). Celiac-disease trials used 0.5 mg (500 mcg) orally before meals; a Phase 3 trial was halted for futility. Taken orally, not injected.

Nonapeptide

No established human dosing; the evidence base is limited and mixed. Research-community sources reference doses on the order of 100-250 mcg.

Porcine brain-derived neuropeptide preparation

Used in several countries (not FDA-approved) for stroke, dementia, and TBI, typically as daily IV/IM courses of roughly 5-30 mL of the commercial solution. Supplied ready-to-use.

Kisspeptin decapeptide fragment

Investigational; administered in research as boluses or infusions to probe reproductive-hormone signaling. No established therapeutic dosing.

Synthetic GnRH decapeptide

Has regulatory-approved diagnostic use (about 100 mcg IV/SC) and pulsatile-pump fertility use (roughly 5-20 mcg per pulse). Also used off-label in the TRT community to support endogenous testicular function.

Pegylated IGF-1 splice variant (Mechano Growth Factor)

No established human dosing; use is investigational/preclinical. Research-community sources reference roughly 200-400 mcg per dose.

Recombinant follistatin isoform (glycoprotein)

No established human dosing for the injected protein; most human research uses AAV gene therapy delivering follistatin. Research-community injectable use is unvalidated.

Synthetic alpha-MSH (MC1R) analog

FDA- and EMA-approved (as Scenesse) for erythropoietic protoporphyria — a 16 mg subcutaneous implant roughly every two months. Research use of the free peptide (melanotan I) is not clinically established.

Topical cosmetic hexapeptide

Cosmetic topical only — formulated in serums and creams, commonly around 5-10%. It is not an injectable, and no systemic dosing is established.

Orally active non-peptide ghrelin receptor (GHS-R1a) agonist / growth hormone secretagogue

Clinical research has examined oral doses commonly around 10-25 mg once daily, studied over weeks to as long as 1-2 years for body composition and bone endpoints. It is not reconstituted or injected. Investigational; not FDA-approved for any indication.

GLP-1 receptor agonist (acylated human GLP-1 analog)

As an approved drug, labeling describes subcutaneous titration - Victoza from 0.6 mg toward 1.2-1.8 mg daily; Saxenda titrated in weekly steps toward 3.0 mg daily. Delivered via prefilled multi-dose pens rather than reconstituted vials. FDA-approved (Victoza 2010; Saxenda 2014).

Long-acting GLP-1 receptor agonist (GLP-1 analog-IgG4 Fc fusion protein)

Labeling describes once-weekly subcutaneous dosing of 0.75 mg or 1.5 mg, with titration options to 3.0 mg and 4.5 mg weekly. Supplied in single-dose prefilled pens/syringes, not reconstituted. FDA-approved (2014).

Nonapeptide neurohypophyseal hormone (9-amino-acid cyclic peptide)

Two distinct contexts: the approved obstetric IV form is dosed in milliunits per minute under clinical supervision, while behavioral research commonly uses intranasal oxytocin around 24 IU (approximately 40 mcg) per session. Approved as an injectable drug (Pitocin) for labor; intranasal social/behavioral use is investigational.

43-amino-acid actin-sequestering peptide (full-length thymosin beta-4)

Research-community protocols for the full-length peptide commonly reference subcutaneous doses in the low-milligram range (often around 2-5 mg per week, sometimes divided) across multi-week cycles; formal human injectable dosing is not established. Distinct from the TB-500 fragment. Investigational; not an approved drug.

11-amino-acid innate repair receptor (IRR) agonist derived from erythropoietin helix-B

Clinical trials have used subcutaneous cibinetide commonly around 4 mg per day for about 28 days in small-fiber neuropathy research, with related regimens explored. Investigational; not an approved drug.

Angiotensin IV-derived oligopeptide analog (HGF/c-Met potentiator)

No established human dosing. Rodent studies have used oral and injected doses in roughly the microgram-to-low-milligram-per-kilogram range; research-community anecdotes cite low-milligram amounts, but these are unsupported by controlled human data. Preclinical/research-only; not approved.

Topical cosmetic octapeptide (SNAP-25 mimetic)

Used topically, typically formulated at around 3-10% of the supplied trade solution in leave-on cosmetic products, applied once or twice daily. It is a cosmetic ingredient, not an approved or injectable drug; no systemic dosing applies.

Topical cosmetic palmitoylated pentapeptide (collagen matrikine)

Cosmetic use references the raw material at low concentrations (commonly around 3-8% of a supplied trade solution) in leave-on creams and serums applied daily. Combination products (e.g., Matrixyl 3000) pair different palmitoyl peptides. Cosmetic ingredient, not an approved or injectable drug.

Pro-apoptotic targeting peptide (prohibitin-homing motif fused to a KLAKLAK apoptotic domain)

No established human dosing. Rhesus primate studies used subcutaneous doses reported around 0.43 mg/kg/day for about 4 weeks, with reversible kidney effects observed. Preclinical/research-only; not approved and not validated for human use.

28-amino-acid vasoactive and immunomodulatory neuropeptide (secretin/glucagon family)

Contexts differ: clinical aviptadil has been studied as a controlled IV infusion (microgram-level dosing), while research-community intranasal VIP protocols cite roughly 50 mcg per spray several times daily. Aviptadil is investigational; VIP is not an approved general-use drug.

Endogenous tripeptide antioxidant (gamma-Glu-Cys-Gly)

Highly route-dependent: IV research/clinical use cites roughly 600-2,400 mg per session; nebulized and subcutaneous protocols use smaller amounts; liposomal oral products aim to offset poor gut absorption. Not FDA-approved as a therapeutic drug (available in compounded injectable and dietary-supplement forms); protocols vary widely.

Zinc-dependent nonapeptide thymic hormone

No established standardized human dosing; experimental and animal studies use microgram-level amounts, and zinc co-availability is emphasized as essential for activity. Investigational/research-only; not an approved drug.

Ciliary neurotrophic factor (CNTF)-derived neurogenic peptide (adamantylated small-peptide derivative)

No human dosing exists. Rodent studies administer it orally (including in diet) or by injection at milligram-per-kilogram levels; there is no validated human protocol. Preclinical/research-only; not approved.

Glycoprotein hormone (gonadotropin)

Dosed in IU and FDA-approved. Clinical and research reports for male testosterone support commonly cite roughly 250-500 IU subcutaneously two to three times weekly, while ovulation induction uses a single dose near 5,000-10,000 IU. Framed as reported, not recommended.

Recombinant peptide hormone (191-amino-acid growth hormone)

Dosed in mg and IU (about 1 mg is 3 IU) and FDA-approved. Adult growth-hormone-deficiency regimens report roughly 0.2-0.4 mg/day subcutaneously titrated to IGF-1; pediatric growth indications are weight-based and higher. Reported, not recommended.

Truncated IGF-1 analog

No approved human use; it is a laboratory and animal research reagent. Non-clinical sources describe small localized amounts (forum figures around 50-100 mcg), but there is no validated or approved human dosing. Reported context only.

IGF-1 splice-variant peptide (IGF-1Ec)

No approved human use; studied in preclinical muscle-repair models. Non-clinical sources describe small localized post-exercise amounts (forum figures around 100-200 mcg) with no validated or approved human dosing. Reported context only.

Recombinant Fc-fusion decoy receptor (ActRIIB-Fc)

Investigational; development was halted. Phase 1 and 2 trials, including in Duchenne muscular dystrophy, reported roughly 1-3 mg/kg subcutaneously every 2-4 weeks before discontinuation in 2013 over bleeding and vascular safety signals. Reported, not recommended.

Small-molecule ERR agonist (not a peptide)

Preclinical only, with no human data and no approval. Rodent studies report intraperitoneal dosing on the order of 50 mg/kg; there is no established human dose. Reported context only.

Small-molecule triple monoamine reuptake inhibitor (not a peptide)

Investigational and not FDA-approved. Phase 2 obesity trials reported roughly 0.25-1.0 mg orally once daily for up to 24 weeks, with the 0.5 mg dose most studied. Reported, not recommended.

Single-chain relaxin-2 peptide analog

No approved or established human dosing; it has been studied only in animal fibrosis and injury models by injection. Reported context only.

Recombinant peptide hormone (relaxin-2)

Investigational and not approved. The RELAX-AHF program administered 30 mcg/kg/day as a continuous 48-hour intravenous infusion in acute heart failure; RELAX-AHF-2 did not meet its primary endpoints. Reported, not recommended.

Short peptide bioregulator (tripeptide)

No approved or validated Western dosing. Russian laboratory, animal, and limited clinical reports describe short injectable courses in the single-digit to roughly 10 mg range; evidence comes largely from one research program. Reported context only.

Thymic peptide bioregulator (polypeptide fraction)

Not FDA-approved, though used as a drug in Russia. Russian clinical reports describe roughly 10 mg intramuscularly once daily for 5-10 day courses; no validated Western dosing exists. Reported, not recommended.

Dipeptide-derived nootropic (small molecule, oral)

Not FDA-approved; a prescription nootropic in Russia and a supplement in some other markets. Studies and label use report roughly 10 mg orally two to three times daily (about 20-30 mg/day); it is oral, not injected. Reported, not recommended.